Table 1.
Types | Reference | Intervention | Study subjects | Sample source | Changes in microbial metabolites | Changes in microbiota | Effects on steatosis |
---|---|---|---|---|---|---|---|
Prebiotics | Kundi et al.127 | OAT, RYE (10% and 10% per day for 17 weeks) |
WD-fed mice | Cecum content-SCFAs and microbiome Feces-BAs |
Up – butyrate, propionate, acetate, T-βMCA Down – CA, DCA |
Up – Bacteroidetes/Firmicutes ratio | Unchanged |
Hong et.al.22 | astragalus polysaccharides (8% per day for 4 weeks) |
HFD-fed mice | Cecum content | Up – purine metabolism Down – glutathione metabolism |
Up – Bacteroidetes
Down – Actinobacteria, Firmicutes, Proteobacteria |
Decreased | |
Xu et al.79 | Sulforaphane (25 mg/kg/day for 6 weeks) |
HFD-fed mice | Serum and liver tissue-IAA Feces-microbiome |
Up – IAA | Up – Bifidobacterium, Romboutsia, Ruminococcaceae_UCG-014
Down – Firmicutes/Bacteroidetes ratio |
Decreased | |
Ma et al.139 | Ferulic acid (30 mg/kg/day for 12 weeks) |
HFD-fed ApoE-/- mice | Serum-metabolites Cecum content-microbiota |
Up – I3A | Up – Bacteroidetes
Down – Firmicutes |
Decreased | |
Huang et al.109 |
Monascus purpureus-fermented common buckwheat (1000 mg/kg/day for 8 weeks) |
HFD-fed mice | Feces | Up – acetate, propionate, butyrate, BAs | Up – Ruminiclostridium, Lacobacillus Alistipes
Down – Bacteroidales S24-7 group, Clostridiales XIII |
Decreased | |
Ye et al.71 | Sodium butyrate (0.6 g/kg/d for 6 weeks) |
MCD diet-fed mice | Feces | Up – stearic acid, behenic acid, oleic acid, linoleic acid, squalene Down – arachidonic acid |
Up – Akkermansia, Roseburia, Coprococcus, Coprobacillus, Delftia, Sutterella, Coriobacteriaceaegenera
Down – Bilophila, Rikenellaceae |
Decreased | |
Amerikanou et al.140 | Mastiha (2.1 g/day for 6 months) |
NAFLD patients (n = 98) | Feces-microbiota Serum-metabolites |
Up – DCA Down – CA |
Up – Faecalibacterium
Down – Flavonifractor, Prevotella, Enterobacteriaceae, Bacteroides |
Decreased PDFF only in obesity | |
Probiotics | Miccheli et al.141 | VSL#3 (1–2 sachets/day for 4 months) |
NAFLD children (n = 31) |
Urine | Down – 2-HIB | / | steatosis grade reduced (evaluated by ultrasound) |
Jena et al.102 | VSL#3 (109 cfu, QW for 7 months) |
WD-fed FXR KO mice | Serum and liver tissue-metabolites Cecum content-microbiota |
Up – CA, CDCA, UDCA, LCA, TLCA Down – DCA, HDCA |
Up – Lachnospiraceae, Ruminococcus Faecalibacterium
Down – Bacteroidaceae, Porphyromonadaceae, Helicobacteraceae |
Decreased | |
Ahmed et al.41 | L. reuteri plus MTZ plus MTF (2 × 109 colony forming unit/day for 8 weeks; 15 mg/kg/day for 1 week; 150 mg/kg/day for 8 weeks) |
HFD-fed male rats | Feces | Restore the ratio of acetate: propionate: butyrate | / | Decreased | |
BAs metabolism modulators | Zhang et al.142 | Gly-MCA (10 mg/kg for 8 weeks) |
HDF-fed mice | Cecum content | Up – T-α-MCA, T-β-MCA Down – acetate, propiorate, butyrate |
Up – Bacteroidetes
Down – Lactobacillus, Firmicutes Actinobacteria |
Downregulated FAs synthesis gene expression |
Zhang et al.143 | OCA (30 mg/kg/day for 12 weeks) |
HFD-fed mice | Feces | Up – CA, α-MCA, βMCA Down – TCA, DCA |
Up – Blautia, Desulfovibrio, Mucispirillum, Ruminiclostridium, Anaerotruncus
Down – Bacteroides, Parabacteroides |
Decreased | |
Clifford et al.112 | GSK2324 (30 mg/kg/day for 3 days) |
WD-fed mice | Cecum content, liver tissue, and gall-bladder | Up – T-β-MCA Down – TCA, CA |
/ | Decreased hepatic TG | |
Matsui et al.93 | IBATi (2.5 μmol/kg/day for 6 weeks) |
HFD-fed mice | Feces | Down – LCA, ω-MCA, βMCA | Up – α-diversity Down – Streptococcaceae |
Decreased |
ApoE, apolipoprotein E; BAs, bile acids; CA, cholic acid; CDCA, chenodeoxycholic acid; DCA, deoxycholic acid; Down, downregulate; FAs, fatty acids; FXR, farnesoid X receptor; Gly-MCA, glycine-β-muricholic acid; HDCA, hyodeoxycholic acid; HFD, high-fat diet; I3A, indole-3-aldehyde; 2-HIB, 2-hydroxybutyrate; IAA, indole-3-acetic acid; IBATi, ileal bile acid transporter inhibitor; KO, knockout; LCA, lithocholic acid; L. reuteri, Lactobacillus reuteri; MCD, methionine-choline-deficient; MTF, metformin; MTZ, metronidazole; NAFLD, non-alcoholic fatty liver disease; OAT, oat bran; OCA, obeticholic acid; PDFF, proton density fat fraction; RYE, rye bran; SCFAs, short-chain-fatty acids; T-βMCA, tauro-β-muricholic acid (T-βMCA); TG, triglyceride; TLCA, taurine-lithocholic acid; UDCA, ursodeoxycholic acid; Up, upregulate; WD, western diet; T-α-MCA, tauro-α-muricholic acid.